Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Agenda
- Neuroendocrine tumors (NETs)
- Multidisciplinary treatment for advanced NETs
- Medical management of unresectable NETs
- Through level 1 evidence: progress is being made!
- Medical treatment for advanced carcinoid in 2016
- Medical treatment for pancreatic NETs 2016
- Somatostatin analogs
- PROMID: Phase 3b study design
- PROMID study results: time to progression
- CLARINET: Phase 3 study design
- CLARINET: progression-free survival
- Pancreatic NETs: targeted trials
- Sunitinib and Everolimus trials
- Summary
- “Carcinoid” GI and lung NETs: targeted trials
- RADIANT-4: Phase 3 study design
- RADIANT-4 study results
- Peptide Receptor Radionuclide Therapy (PRRT)
- NETTER-1: Phase 3 study design - Role of PRRT
- NETTER-1 study results: progression-free survival
- NETTER-1 study results: overall survival analysis
- Cytotoxic chemotherapy and advanced NETs
- Potential indications for chemotherapy
- Putting it all together
- Unresectable/metastatic extra-pancreatic NETs
- Unresectable/metastatic pancreatic NETs
- Concluding remarks – part 1
Topics Covered
- General background on neuroendocrine tumors (NETs)
- Medical management of NETs (current therapy options as of 2016 for extra-pancreatic NETs and pancreatic NETs)
- Factors associated with response to immunotherapy in cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Raj, N. (2017, January 30). Immunotherapy in neuroendocrine tumors 1 - current available therapy options [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 9, 2024, from https://doi.org/10.69645/CIDM1730.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Nitya Raj has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Immunotherapy in neuroendocrine tumors 1 - current available therapy options
Published on January 30, 2017
18 min
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
So thank you for the opportunity
to speak today.
My name is Nitya Raj.
I am one of the Assistant
Attending Physicians
in the Gastrointestinal
Oncology Service
at Memorial Sloan
Kettering Cancer Center.
My clinical practice is devoted
to the care of patients
with gastrointestinal cancers,
particularly neuroendocrine tumors.
And I'm a clinical researcher
who focuses my research activities
on identifying new therapies
for patients
with neuroendocrine tumors.
In addition,
I'm also studying ways to improve
our understanding
of the tumor biology
of this rare group of cancers,
particularly understanding
how neuroendocrine tumors
change genetically over time
and as a result
of different treatments.
So today,
I'm going to be speaking to you
about immunotherapy
in neuroendocrine tumors.
0:51
Okay, so here is the agenda
that we'll be focusing on today.
First, I'm going to give
a brief background
on neuroendocrine tumors.
I'll then highlight
our current therapy options
that are available as of 2016.
I'll move on to then discuss
what has already been done
to evaluate for a role
of immunotherapy,
and I'm going to take us back
to what's been done previously
both in the clinic
and in the lab,
and I'll conclude the talk
by discussing
where we can go from here
and how we can use the data
we already have
to develop clinical trials
for immunotherapy
in neuroendocrine tumors.
1:31
So just to give a brief background
on neuroendocrine tumors,
and I'd like to begin my talk
by using the phrase,
"What's in a name?"
And I'd like to use this phrase
to really emphasize
that neuroendocrine tumors
can develop anywhere
in the body.
Although,
this is a rare group of cancers,
they are increasing
in both incidence and prevalence
just in the past few decades.
So in the early 1970s,
the incidence was estimated
at 1 per 100,000 cases,
and more recently,
it is now rising
to approximately 5 per 100,000.
It's unknown if this trend
of increasing incidence
and prevalence
is truly due to better
recognition of the tumors
rather than an increase
in incidence and prevalence.
These tumors are classified
by their location,
and the big distinction comes
from whether they begin
in the pancreas or not.
And so tumors that start outside
of the pancreas
are often termed carcinoid tumors
whereas those that begin
in the pancreas
are termed pancreatic
neuroendocrine tumors.
The primary sites of origin,
neuroendocrine tumors are either
in the gastrointestinal tract
or in the thoracic cavity.
And the majority of our patients
present with advanced
metastatic disease
as these tumors
are often characterized
by indolent behavior
and symptom
and are only recognized
after much progression,
Hide